We are live on ! Find out more
VM

VV Manager Portfolio holdings

AUM $114M Turnover 0%
1-Year Est. Return 59.16%
This Fund
S&P 500
This Quarter Est. Return
+80.39%
1 Year Est. Return
+59.16%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$114M
AUM Growth
+$25.5M
Cap. Flow
-$18.8M
Cap. Flow %
-16.46%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
2
Closed
–
Avg Time Held
1.2 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.2 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALLO icon
Allogene Therapeutics
ALLO
+$17.8M
2
STRO icon
Sutro Biopharma
STRO
+$952K

Sector Composition

Rank Sector Weight
1 Healthcare 80.28%
2 Miscellaneous 19.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALLO icon
1
Allogene Therapeutics
ALLO
$449M
$77M 67.53%
1,798,163
-492,553
-22% -$17.8M
2018 Q4
6 quarters
QTTB icon
2
Q32 Bio
QTTB
$232M
$11.7M 10.27%
42,825
– –
2018 Q4
6 quarters
STRO icon
3
Sutro Biopharma
STRO
$187M
$2.84M 2.49%
36,566
-9,920
-21% -$952K
2018 Q4
6 quarters

Similar funds

MCM
Maxim Capital Management San Francisco, California $112M AUM 0.1% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
APG
Andrew P. Goldfarb $102M AUM 9.91% 1-Year Est. Return
LM
Legg Mason Baltimore, Maryland $127M AUM 6.76% 1-Year Est. Return
VPMV
Venrock Partners Management V Palo Alto, California $101M AUM
CCM
Castine Capital Management Boston, Massachusetts $129M AUM 23.45% 1-Year Est. Return
CCM
Cloverdale Capital Management Dallas, Texas $135M AUM 13.89% 1-Year Est. Return
MCMT
Moon Capital Management (Tennessee) Knoxville, Tennessee $82.4M AUM 3.53% 1-Year Est. Return

VV Manager's Q2 2020 Portfolio in Review

As of Q2 2020, VV Manager held 4 positions worth $114M, up 29% from $88.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

VV Manager withdrew a net $18.8M in Q2 2020, reducing 2 holdings. Its largest reduction was Allogene Therapeutics, cutting an estimated $17.8M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 69% a quarter earlier, followed by Miscellaneous.

  • VV Manager's biggest Q2 2020 reduction was Allogene Therapeutics, cutting an estimated $17.8M.
  • VV Manager's ten largest holdings make up 100% of its $114M portfolio in Q2 2020.
  • VV Manager opened 0 new positions and closed 0 in Q2 2020.
  • VV Manager's portfolio value rose 29% quarter-over-quarter to $114M.

Based on VV Manager's 13F filing for Q2 2020, filed 4 Aug 2020.